AMENDMENTS TO THE CLAIMS

What is claimed is:

1. (currently amended) An endoprosthesis, comprising:

a carrier structure comprising a metallic material;

wherein the metallic material comprises a magnesium alloy of the following composition:

Magnesium:	>90%
Yttrium:	3.7% - 5.5%
Rare earths:	1.5% - 4.4% and
Balance:	<1%.

2. (original) The endoprosthesis of claim 1, wherein:

the yttrium proportion in the magnesium alloy is between 4% and 5%.

3. (original) The endoprosthesis of claim 1, wherein:

the rare earths proportion in the magnesium alloy is between 1.5% and 4%.

4. (original) The endoprosthesis of claim 1, wherein:

the rare earths proportion in the magnesium alloy comprises neodymium.

5. (original) The endoprosthesis of claim 1, wherein:

the balance proportion in the magnesium alloy is formed for the major part by zirconium.

6. (original) The endoprosthesis of claim 1, wherein:

the carrier structure consists essentially of the magnesium alloy.

7. (currently amended) The endoprosthesis of claim 1, wherein:

the carrier structure ~~is extruded~~ provides a cell survival rate of over about 70 percent upon cultivation of smooth muscle cells with the eluate of the material of

the carrier structure in comparison with untreated cells, or a proliferation inhibition effect below about 20 percent with respect to untreated smooth muscle cells.

8. (original) The endoprosthesis of claim 1, wherein:
the endoprosthesis is in the form of an intraluminal endoprosthesis.

9. (original) The endoprosthesis of claim 8, wherein:
the endoprosthesis is in the form of a stent.

10. (original) The endoprosthesis of claim 9, wherein:
the endoprosthesis is in the form of a coronary stent.

11. (original) The endoprosthesis of claim 9, wherein:
the endoprosthesis is in the form of a self-expanding stent.

12. (original) The endoprosthesis of claim 1, wherein:
the carrier structure is produced by cutting a tube from one piece.

13. (original) The endoprosthesis of claim 1, wherein:
the carrier structure is formed from a wire which contains the magnesium alloy.

14. (original) The endoprosthesis of claim 1, wherein:
the carrier structure encloses an elongated hollow space which is open at its ends.

15. (original) The endoprosthesis of claim 14, wherein:
the carrier structure is of a lattice-like structure and is formed by a plurality of legs and radial openings enclosed by said plurality of legs.

16. (original) The endoprosthesis of claim 15, wherein:

the plurality of legs all have a similar cross-sectional area such that a ratio of largest to smallest cross-sectional area is smaller than 2.

17. (original) The endoprosthesis of claim 15, wherein:
the plurality of legs all have a similar minimum diameter such that a ratio of largest to smallest minimum diameter is less than 2.

18. (original) The endoprosthesis of claim 15, wherein:
a first plurality of the plurality of legs form leg rings and a second plurality of the plurality of legs define connecting legs that connect adjacent leg rings together, wherein the connecting legs are of a smaller cross-sectional area or a smaller minimum diameter than the legs which form the leg rings.

19. (original) The endoprosthesis of claim 1, wherein:
the endoprosthesis carries a physiologically effective active substance.

20. (original) The endoprosthesis of claim 19, wherein:
the endoprosthesis is coated with at least one drug.

21. (original) The endoprosthesis of claim 2, wherein:
the carrier structure consists essentially of the magnesium alloy.

22. (original) The endoprosthesis of claim 3, wherein:
the carrier structure consists essentially of the magnesium alloy.

23. (original) The endoprosthesis of claim 4, wherein:
the carrier structure consists essentially of the magnesium alloy.

24. (original) The endoprosthesis of claim 5, wherein:
the carrier structure consists essentially of the magnesium alloy.

25. (currently amended) The endoprosthesis of claim 2, wherein:
the carrier structure ~~is extruded~~ provides a cell survival rate of over about 70 percent upon cultivation of smooth muscle cells with the eluate of the material of the carrier structure in comparison with untreated cells, or a proliferation inhibition effect below about 20 percent with respect to untreated smooth muscle cells.

26. (currently amended) The endoprosthesis of claim 3, wherein:
the carrier structure ~~is extruded~~ provides a cell survival rate of over about 70 percent upon cultivation of smooth muscle cells with the eluate of the material of the carrier structure in comparison with untreated cells, or a proliferation inhibition effect below about 20 percent with respect to untreated smooth muscle cells.

27. (currently amended) The endoprosthesis of claim 4, wherein:
the carrier structure ~~is extruded~~ provides a cell survival rate of over about 70 percent upon cultivation of smooth muscle cells with the eluate of the material of the carrier structure in comparison with untreated cells, or a proliferation inhibition effect below about 20 percent with respect to untreated smooth muscle cells.

28. (currently amended) The endoprosthesis of claim 5, wherein:
the carrier structure ~~is extruded~~ provides a cell survival rate of over about 70 percent upon cultivation of smooth muscle cells with the eluate of the material of the carrier structure in comparison with untreated cells, or a proliferation inhibition effect below about 20 percent with respect to untreated smooth muscle cells.

29. (currently amended) The endoprosthesis of claim 6, wherein:
the carrier structure ~~is extruded~~ provides a cell survival rate of over about 70 percent upon cultivation of smooth muscle cells with the eluate of the material of

the carrier structure in comparison with untreated cells, or a proliferation inhibition effect below about 20 percent with respect to untreated smooth muscle cells.

30. (original) The endoprosthesis of claim 9, wherein:
the endoprosthesis is in the form of a peripheral stent.

31. (original) The endoprosthesis of claim 9, wherein:
the endoprosthesis is in the form of a balloon-expandable stent.

32. (original) The endoprosthesis of claim 10, wherein:
the endoprosthesis is in the form of a self-expanding stent.

33. (original) The endoprosthesis of claim 30, wherein:
the endoprosthesis is in the form of a self-expanding stent.

34. (original) The endoprosthesis of claim 10, wherein:
the endoprosthesis is in the form of a balloon-expandable stent.

35. (original) The endoprosthesis of claim 30, wherein:
the endoprosthesis is in the form of a balloon-expandable stent.

36. (original) The endoprosthesis of claim 16, wherein:
a first plurality of the plurality of legs form leg rings and a second plurality of the plurality of legs define connecting legs that connect adjacent leg rings together, wherein the connecting legs are of a smaller cross-sectional area or a smaller minimum diameter than the legs which form the leg rings.

37. (original) The endoprosthesis of claim 17, wherein:
a first plurality of the plurality of legs form leg rings and a second plurality of the plurality of legs define connecting legs that connect adjacent leg rings together,

wherein the connecting legs are of a smaller cross-sectional area or a smaller minimum diameter than the legs which form the leg rings.